• 1
    Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992;70: 5236.
  • 2
    Hiyama T, Yokozaki H, Shimamoto F, Haruma K, Yasui W, Kajiyama G, Tahara E. Frequent p53 gene mutations in serrated adenomas of the colorectum. J Pathol 1998;186: 1319.
  • 3
    Marx J, Momand J, Finlay CA. How p53 suppresses cell growth. Science 1993;262: 16445.
  • 4
    Frebourg T, Friend SH. The importance of p53 gene alterations in human cancer: is there more than circumstantial evidence? J Natl Cancer Inst 1993;85: 15547.
  • 5
    Jensen RA, Page DL. p53: the promising story continues to unfold. Hum Pathol 1993;24: 4556.
  • 6
    Roy B, Beamen J, Balint E, Reisman D. Transactivation of the human p53 tumor suppressor gene by c-myc/max contributes to elevated mutant p53 expression in some tumors. Mol Cell Biol 1994;14: 780515.
  • 7
    Storay A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393: 22934.
  • 8
    Rosenthal AN, Ryan A, Al-Jehani RM, Storey A, Harwood CA, Jacobs IJ. p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet 1998;352: 8712.
  • 9
    Weston A, Ling-Cawley HM, Capaoraso NE, Bowman ED, Hoover RN, Trump BF, Harris CC. Determination of the allele frequencies of an L-myc and a p53 polymorphism in human lung cancer. Carcinogenesis 1994;14: 5837.
  • 10
    Fan R, Wu M-T, Miller D, Wain JC, Kelsey KT, Wiencke JK, Christiani DC. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000;9: 103742.
  • 11
    Lee J-M, Lee Y-C, Yang S-Y, Shi W-L, Lee C-J, Luh S-P, Chen C-J, Hsieh C-Y, Wu M-T. Genetic polymorphisms of p53 and GSTP1, but not NAT2, are associated with susceptibility to squamous-cell carcinoma of the esophagus. Int J Cancer 2000;89: 45864.
  • 12
    Kawaguchi H, Ohno S, Araki K, Miyazaki M, Saeki H, Watanabe M, Tanaka S, Sugimachi K. p53 polymorphism in human papillomavirus-associated esophageal cancer. Cancer Res 2000;60: 27535.
  • 13
    Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. 1998. CA Cancer J Clin 1998;48: 629.
  • 14
    Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52: 673540.
  • 15
    Hiyama T, Yokozaki H, Kitadai Y, Tahara E, Tahara H, Ide T, Haruma K, Yasui W, Kajiyama G, Tahara E. In situ mRNA hybridization technique for analysis of human telomerase RNA in gastric precancerous and cancerous lesions. Jpn J Cancer Res 1998;89: 118794.
  • 16
    Haruma K, Komoto K, Ito M, Kitadai Y, Yoshihara M, Sumii K, Kajiyama G. Helicobacter pylori infection is a major factor for gastric carcinoma in young patients. Scand J Gastroenterol 2000;35: 2559.
  • 17
    Shepherd T, Tolbert D, Bnenedetti J, MacDonald J, Stemmermann G, Wiest J, DeVoe G, Miller MA, Wang J, Noffsinger A, Fenoglio-Preiser C. Alterations in exon 4 of the p53 gene in gastric carcinoma. Gastroenterology 2000;118: 103944.
  • 18
    Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma. An attempt at a histoclinical classification. Acta Pathol Microbiol Scand 1965;64: 3149.
  • 19
    Japanese Research Society for Gastric Cancer. Classification of gastric carcinoma. English ed. Tokyo: Kanehara, 1995.
  • 20
    Dixon MF, Genta MF, Rardley JH, Correa P. Classification and grading of gastritis: the Updated Sydney System. Am J Surg Pathol 1996; 20116181.
  • 21
    Ara S, Lee PS, Hansen MF, Saya H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res 1990;18: 4961.
  • 22
    Talley NJ, Zinsmeister AR, Weaver A, Dimagno EP, Carpenter HA, Perez GI, Blaser MJ. Gastric adenocarcinoma and Helicobacter pylori infection. J Natl Cancer Inst 1991;83: 17349.
  • 23
    IARC Working Group on The Evaluation of Carcinogenic Risks to Humans. Helicobacter pylori. Schistosomes, liver flukes, and Helicobacter pylori: views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon: IARC, 1994. 177240.
  • 24
    Tahara E. Molecular mechanism of stomach carcinogenesis. Cancer Res Clin Oncol 1993;119: 26572.
  • 25
    Wu MS, Shun CT, Wang HP, Sheu JC, Lee WJ, Wang TH, Lin JT. Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection. Gastroenterology 1997;112: 145765.
  • 26
    Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and development of gastric cancer. N Engl J Med 2001;345: 7849.
  • 27
    Gunn MC, Stephens JC, Stewart JAD, Rathbone BJ, West KP. The significance of cagA and vacA subtypes of Helicobacter pylori in the pathogenesis of inflammation and peptic ulceration. J Clin Pathol 1998;51: 7614.
  • 28
    Basso D, Navaglia F, Brigato L, Piva MG, Toma A, Greco E, DiMario F, Galeotti F, Roveroni G, Corsini A, Plebani M. Analysis of Helicobacter pylori vacA and cagA genotypes and serum antibody profile in benign and malignant gastroduodenal diseases. Gut 1998;43: 1826.
  • 29
    Maeda S, Ogura K, Yoshida H, Kanai F, Ikenoue T, Kato N, Shiratori Y, Omata M. 1998. Major virulence factors, VacA and CagA, are commonly positive in Helicobacter pylori isolates in Japan. Gut 1998;42: 33843.
  • 30
    Matlashewski GS, Tuck D, Pim P, Lamb J, Schneider J, Crawford L. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987;7: 9613.
  • 31
    Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild type p53 differ biochemically and biologically. Mol Cell Biol 1999;19: 1092100.
  • 32
    Jin X, Wu X, Roth JA, Amos CI, King TM, Branch C, Honn SE, Spitz MR. Higher lung cancer risk for young African-Americans with the pro/pro p53 genotype. Carcinogenesis 1995;16: 22058.
  • 33
    Murata M, Tagawa M, Kimura M, Kimura H, Watanabe S, Saisho H. Analysis of a germ line polymorphism of the p53 gene in lung cancer patients: discrete results with smoking history. Carcinogenesis 1996;17: 2614.
  • 34
    Sjalander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, Beckman G, Beckman L. P53 polymorphism and haplotypes in breast cancer. J Carcinogenesis 1996;17: 13136.
  • 35
    Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J. Cancer incidence in five continents. IARC Scientific Publication 1997;143: 8223.
  • 36
    Kaneko S, Yoshimura T. Time trend analysis of gastric cancer incidence in Japan by histological types, 1975–1989. Br J Cancer 2001;84: 4005.
  • 37
    Meining A, Stolte M, Hatz R, Lehn N, Mielke S, Morgner A, Bayerdörffer E. Differing degree and distribution of gastritis in Helicobacter pylori-associated diseases. Virchows Arch 1997;431: 115.
  • 38
    Wang YC, Chen CY, Chen SK, Chang YY, Lin P. p53 codon polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin Cancer Res 1999;5: 12934.
  • 39
    Ninomiya Y, Yanagisawa A, Kato Y, Kitagawa T, Ishihara S, Nakajima T. Histological indications of a favorable prognosis with far-advanced gastric carcinomas after preoperative chemotherapy. J Cancer Res Clin Oncol 1999;125: 699706.
  • 40
    Chen MJ, Chiou YY, Wu DC, Wu SL. Lifestyle habits and gastric cancer in hospital-based case-control study in Taiwan. Am J Gastroenterol 2000;95: 32429.
    Direct Link:
  • 41
    Palli D, Russo A, Decarli A. Dietary patterns, nutrient intake and gastric cancer in a high-risk area of Italy. Cancer Causes Control 2001;12: 16372.
  • 42
    Setiawan VW, Zhang ZF, Yu GP, Lu QY, Li YL, Lu ML, Wang MR, Guo CH, Yu SZ, Kurtz RC, Hsieh CC. Protective effect of green tea on the risks of chronic gastritis and stomach cancer. Int J Cancer 2001;92: 6004.